Furthermore, RUNX1 mutations in our elderly cohort clustered among patients identified with intermediate cytogenetic risk including cytogenetically-normal AML, consistent with previous studies [7,10]. This evidence concerns the gene RUNX1 and acute myeloid leukemia.